Deferred tax assets |
|
|
March 31, |
|
|
|
2016 |
|
|
2015 |
|
Deferred tax assets: |
|
|
|
|
|
|
|
|
Net
operating loss carryforwards |
|
$ |
36,454,000 |
|
|
$ |
36,661,000 |
|
Research
and development tax credit carryforwards |
|
|
1,710,000 |
|
|
|
1,667,000 |
|
Stock-based
compensation |
|
|
5,083,000 |
|
|
|
4,880,000 |
|
Reserves
and accruals |
|
|
1,111,000 |
|
|
|
1,731,000 |
|
Other
deferred tax assets |
|
|
241,000 |
|
|
|
49,000 |
|
State
income taxes |
|
|
(1,000 |
) |
|
|
(1,000 |
) |
Basis
difference in assets |
|
|
8,000 |
|
|
|
5,000 |
|
Total
deferred tax assets |
|
$ |
44,606,000 |
|
|
$ |
44,992,000 |
|
Deferred tax liabilities: |
|
|
|
|
|
|
|
|
Unrealized
gain on Ruthigen |
|
|
|
|
|
|
(1,105,000 |
) |
Net deferred tax asset |
|
|
44,606,000 |
|
|
|
43,887,000 |
|
Valuation allowance |
|
|
(44,606,000 |
) |
|
|
(43,887,000 |
) |
Net deferred tax asset |
|
$ |
|
|
|
$ |
|
|
|
Schedule of income tax expense |
|
|
Years Ended March 31, |
|
|
|
2016 |
|
|
2015 |
|
Income tax (benefit) |
|
$ |
(719,000 |
) |
|
$ |
(2,613,000 |
) |
Change in valuation allowance |
|
|
719,000 |
|
|
|
2,613,000 |
|
Net income tax expense |
|
$ |
|
|
|
$ |
|
|
|